



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2015 Certified Company
CIN No. : L24239MH1988PLC047759

SYNCOM/SE/2021-22

14th February, 2022

Online Filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
P.J. Towers
Dalal Street, Fort,
Mumbai - 400001 (M.H.)

BSE CODE: 524470

Subject: Submission of the Standalone Un-audited Financial Results & Limited Review Report for the Quarter and Nine Months ended 31st December, 2021 as per Regulation 33 of SEBI (LODR) Regulations, 2015.

Dear Sir/Ma'am,

This is in continuation of our letter no. SYNCOM/SE/2021-22 dated 3rd February, 2022 regarding intimation of Board meeting for consideration and approval of the Quarterly Un-audited Financial Results for the Quarter and Nine Months ended 31st December, 2021.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-audited Financial Results and Limited Review Report by Auditors for the quarter ended 31st December, 2021, in PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on Monday, 14th February, 2022.

The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed format for that purpose.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company www.sfil.in.

You are requested to take on record the above said Un-audited Financial Results & Limited Review Report for your reference and record.

Thanking You,
Yours Faithfully,

For, SYNCOM FORMULATIONS (INDIA) LIMITED

Prachi

CS PRACHI JAIN
COMPANY SECRETARY &
COMPLIANCE OFFICER

Encl: Standalone Un-audited Financial Results and Limited Review Report.



Bringing a smile on every face...



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7 Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai - 400 093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2021

(Rs. In Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Revenue from Operations	5722.60	5293.69	8416.99	16143.23	17926.32	24480.51
2	Other Income	223.54	272.49	119.72	629.08	340.94	714.10
3	Total Income (1 + 2)	5946.14	5566.18	8536.71	16772.31	18267.26	25194.61
4	EXPENSES						
	(a) Cost of materials consumed	3123.61	2256.31	3337.53	7454.76	7246.84	9909.54
	(b) Purchases of Stock-in-Trade	1234.36	1160.03	2846.15	3146.52	5230.96	6641.28
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(554.08)	(179.01)	(314.90)	(256.67)	(293.64)	(404.67)
	(d) Employee benefits expense	598.53	510.35	498.19	1605.17	1260.02	1966.56
	(e) Finance costs	15.39	12.02	3.38	46.26	11.54	27.11
	(f) Depreciation and amortization expense	99.20	97.38	98.63	293.68	298.53	403.49
	(g) Other expenses	830.24	979.05	745.91	2436.65	1539.39	2583.90
	Total expenses (4)	5347.25	4836.12	7214.88	14726.37	15293.63	21127.21
5	Profit/(loss) before exceptional items and tax (3- 4)	598.89	730.06	1321.83	2045.94	2973.63	4067.40
6	Add /(Less) : Exceptional Items	0.00	0.00	0.00	3.48	0.00	3.00
7	Profit/(loss) before tax (5 + 6)	598.89	730.06	1321.83	2049.42	2973.63	4070.40
8	Tax expense:						
	(1) Current tax	173.17	166.72	318.00	521.17	741.00	1130.08
	(2) Deferred tax	24.41	1.16	1.58	24.98	10.32	23.11
9	Profit (Loss) for the period from continuing operations (7-8)	401.31	562.18	1002.24	1503.27	2222.30	2917.21
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	401.31	562.18	1002.24	1503.27	2222.30	2917.21
14	Other Comprehensive Income						
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	174.85	(48.12)	40.41	197.17	53.04	65.58
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	576.16	514.07	1042.65	1700.44	2275.34	2982.79
16	Paid up Share Capital of the Company (Face Value 1/-)	8299.53	8299.53	7806.52	8299.53	7806.52	7899.52
17	Reserves excluding revaluation reserves						9883.57
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.07	0.06	0.13	0.21	0.29	0.38
	(2) Diluted	0.06	0.06	0.13	0.19	0.29	0.37
19	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.07	0.06	0.13	0.20	0.29	0.38
	(2) Diluted	0.06	0.06	0.13	0.19	0.29	0.37

Place: Indore
Date: 14/02/2022

For, Syncom Formulations (India) Limited

Kedarnath Shankarlal Bankda
Chairman & Wholtime Director
DIN: 00023050





SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7 Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400 093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTER/NINE MONTHS RESULTS

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a) Pharmaceuticals Drugs & Formulations	5520.24	5324.59	6837.31	16006.79	15198.90	21888.05
	b) Trading of Commodities	353.53	184.17	1634.12	570.84	2855.73	3027.40
	c) Renting of Property	72.37	57.42	65.29	194.68	212.63	279.16
	Total Segment Revenue	5946.14	5566.18	8536.72	16772.31	18267.26	25194.61
	Less: Inter Segment Revenue		0.00	0.00	0.00	0.00	0.00
	Revenue from Operations	5946.14	5566.18	8536.72	16772.31	18267.26	25194.61
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment						
	a) Pharmaceuticals Drugs & Formulations	531.82	666.91	1239.76	1873.44	2719.78	3741.05
	b) Trading of Commodities	6.60	17.75	20.15	27.55	52.76	74.29
	c) Renting of Property	72.37	57.42	65.29	194.68	212.63	279.16
	Total Profit before tax	610.79	742.07	1325.20	2095.67	2985.17	4094.50
	Less: i) Interest	15.39	12.02	3.38	46.27	11.54	27.11
	Add: ii) Other Un-allocable Expenditure	3.48	0.00	0.00	3.48	0.00	3.00
	Profit before tax	598.88	730.06	1321.82	2052.8873	2973.63	4070.39
3	(Segment Asset-Segment Liabilities)						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	28864.08	25362.79	20334.97	28864.08	20334.97	22495.62
	b) Trading of Commodities	157.82	324.90	678.53	157.82	678.53	1901.79
	c) Renting of Property	4713.34	4760.47	4784.08	4713.34	4784.08	4767.56
	Total Segment Asset	33735.24	30448.16	25797.58	33735.24	25797.58	29164.97
	Un-allocable Assets		0.00	0.00	0.00	0.00	0.00
	Net Segment Asset	33735.24	30448.16	25797.58	33735.24	25797.58	29164.97
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	7721.12	9654.29	8764.05	7721.12	8764.05	10035.22
	b) Trading of Commodities	93.42	5.84	16.58	93.42	16.58	208.50
	c) Renting of Property	4713.34	153.35	176.55	4713.34	176.55	162.85
	Total Segment Liabilities	12527.88	9813.48	8957.18	12527.88	8957.18	10406.57
	Un-allocable Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Liabilities	12527.88	9813.48	8957.18	12527.88	8957.18	10406.57

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14/02/2022.
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/nine months ended on 31st December, 2021. The report does not have any impact on the above results and notes which needs to be filed.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs. 926.85 Lakhs by conversion of 4,93,00,820 warrants to 4,93,00,820 equity shares of Rs. 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs. 1962.61 Lakhs. Out of which the company has already utilized the amount of Rs. 226.54 Lakhs being the work is completed and capitalized as well as Rs. 834.02 Lakhs is utilized towards the continuing ongoing capital work in progress, total Rs. 1060.56 Lakhs. Remaining unutilized amount of Rs. 902.05 Lakhs will be used in the subsequent period. There is no deviation in the project till 31st Dec, 2021 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. separately.

Place: Indore

Date: 14/02/2022



For, Syncom Formulations (India) Limited

Kedarnath Shankar Lal Bankda

Chairman & Wholtime Director

DIN: 00023050

SANJAY MEHTA & ASSOCIATES

Chartered Accountants

338, Saket Nagar, Indore - 452 018

Phone/Telefax : 0731-4274391, 2563625

E-mail:sanjaymehta.associates@gmail.com

Limited Review Report on the Quarter and Nine Months ended Un-audited Standalone Financial Results pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company")**, for the period ended December 31, 2021 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C



CA Manish Mittal
(Partner)

M. No. 079452

UDIN: 22079452ACDMSS2670

Place: Indore

Date: 14th February, 2022